NIPT
Aetna Revises Fetal Aneuploidy Screening Policy to Include Natera, BillionToOne Tests
The policy considers cfDNA testing medically necessary in cases such as a risk of alloimmunization and where amniocentesis is declined or contraindicated.
The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.
Devyser Fetal RHD Screening Test Receives IVDR Certification
The qPCR-based test can help determine the rhesus D antigen status of the fetus in a pregnant woman.
Devyser Fetal Abnormality Test Nabs China Approval; Firm, Thermo Fisher Collaborate on FDA Approval
The fetal abnormality test measures the most common chromosomal abnormalities, including Down syndrome, via a single-tube PCR process.
Natera Reports 52 Percent Spike in Q1 Revenues, Raises Full-Year Guidance
The company beat analysts' estimates on the top and bottom lines with growth driven by increased testing volumes and improvements in average test selling price.
Dec 22, 2023
Wells Fargo Initiates Coverage of Revvity
Jul 31, 2023
Juno Diagnostics Ceases Commercial Operations
Apr 19, 2023
Ravgen Prevails Over Streck in Patent Challenge
Apr 17, 2023
Illumina, Ravgen Settle Patent Lawsuit Over NIPTs
Jan 25, 2023
Ravgen NIPT Patents Withstand Illumina Challenge
Dec 6, 2022